objective To evaluate the usefulness of early acute kidney injury (AKI) biomarkers in clinical management of visceral leishmaniasis.
Introduction
Visceral leishmaniasis (VL), also known as kala-azar, a disease caused by parasites of the Leishmania genus, is a potentially fatal parasitic disease if left untreated [1] . VL severity depends on the Leishmania species and the host's immune response [2] . VL patients may have intense parasitism of the reticuloendothelial system with marked anaemia, leukopenia, thrombocytopenia and an important increase in plasma gamma globulin levels [3] . VL affects approximately 400 000 people around the world and is responsible for up to 40 000 deaths per year [4] . In Brazil, VL is endemic with 3298 cases in 2015, being responsible for 272 deaths, with a lethality rate of almost 8% [5, 6] . VL-associated nephropathy has been related with higher mortality in these patients [7] [8] [9] .
Acute kidney injury (AKI) is a frequent manifestation in VL (up to 46%), being related with amphotericin B use, secondary infections, hemodynamic abnormalities and the parasitic infection itself [7] . Early AKI diagnosis is crucial to prevent further renal complications, need for dialysis and even death. In fact, the delay in AKI diagnosis is partly due to the use of a serum creatininebased criteria such as RIFLE, AKIN and KDIGO classifications, where the increased level appears when kidney injury is already advanced [10] . Hence, novel kidney injury biomarkers have been widely studied with a paramount importance in early detection of kidney injury in different clinical settings [11] .
Promising AKI biomarkers for use in clinical practice include kidney injury molecule-1 (KIM-1) and human neutrophil gelatinase-associated lipocalin (NGAL). Human NGAL has been extensively studied as a novel biomarker of kidney injury [12, 13] . It belongs to the lipocalin family, extracellular proteins with a molecular mass of 25 kDa [14] . NGAL is produced and secreted by activated neutrophils and poorly expressed in other tissues during normal conditions, including the kidney [15] . Due to its degradation resistance and small molecular size, NGAL is readily excreted and easily detected in the urine [16] . Also, NGAL expression is induced in the proximal and distal nephron segments during kidney injury, resulting in elevated serum and urinary levels [17, 18] . Both urine and serum NGAL levels have been evaluated in a variety of diseases as an independent predictor of AKI, with high sensitivity and specificity in the early diagnosis of AKI onset [17] .
To the best of our knowledge, there are no studies evaluating the role of NGAL and KIM-1 in VL-associated nephropathy. In a preliminary study of our group with VL patients, elevated levels of urinary MCP-1 (a promising new biomarker of chronic kidney disease) were observed before the start of specific treatment in a crosssectional design [19] . Considering that amphotericin B is the most effective treatment against Leishmania and it is a potentially nephrotoxic drug [1] , early diagnosis of kidney injury in VL patients may direct better clinical management strategies. Hence, we hypothesised that NGAL, urinary MCP-1 and urinary KIM-1 levels may provide new insights about VL-associated nephropathy and also predict or identify patients at higher risk for AKI development during hospital stay.
Materials and methods

Study design and VL patient selection
We performed a prospective and single-centre study from April 2015 to January 2017, at São Jos e Hospital, a reference hospital for Infectious Diseases in the state of Cear a, Northeast of Brazil.
The inclusion criteria were age between 18 and 65 years and confirmed diagnosis of visceral leishmaniasis (VL). VL diagnosis was based on serologic tests (use of recombinant antigen K-39) and parasite identification in bone marrow aspirate. We excluded patients with hospital stay <48 h, those with previous kidney diseases and admission serum creatinine levels >2 mg/dl, diuretic users and patients with hypertension and diabetes mellitus. Therefore, we aimed to exclude risk factors for kidney disease by evaluating only VL infection and its treatment effect.
All suspected cases of visceral leishmaniasis presenting at hospital had blood and urine samples collected. All samples were collected at admission and before the start of VL treatment. After that, patients with a confirmed diagnosis and those who met the inclusion criteria, including a hospital stay longer than 48 h, were selected and analysed in this study. Patients were followed up to hospital discharge (median follow-up time of 11 days). A healthy control group matched for sex and age was also enrolled. The control group comprised participants with confirmed absence of any comorbidities or pathological conditions at the time of sample collection. It consisted of nurses, pharmacists, residents and medical students of the institution who volunteered to participate. The study protocol was reviewed and approved by the Ethics Committee of the Federal University of Ceara (CAAE: 41685514.3.3001.5044), and all participants gave written informed consent prior to study enrolment.
Sample processing
Urine was centrifuged at 1000 g for 15 min at 4°C to remove urinary sediments, including whole cells and other debris. The urine supernatant was aliquoted and immediately stored at À80°C until use. Venous blood was collected in BD Vacutainer â SST with silica clot activator and a polymer gel for efficient serum separation. After 15 min the blood samples were centrifuged, and the serum was obtained. Specific serum aliquots were separated for biochemical measurements, while others were used to quantify new biomarkers. Also, serum samples were stored at À80°C until the analyses were performed.
Biochemical and renal function evaluation
Standard biochemical analyses were performed using a routine automated analyser provided by the São Jos e Hospital laboratory. Serum sodium and potassium were determined in an ion selective electrolyte analyser (9180, Electrolyte Analyzer, Roche â ) and the results were expressed as mEq/l. Glomerular Filtration Rate (eGFR) was estimated using the CKD-EPI formula [20] .
Urinary albumin was measured by immunoturbidimetry assay using an automated analyser (Cobas C111, Roche â ). Also, urinary creatinine was measured in a Cobas C111 analyser, Roche â . Urine total protein excretion was quantified by the colorimetric pyrogallol red method (Labtest â ). Urinary albumin and total protein by the urinary creatinine ratio were calculated, resulting in the urinary albumin/creatinine (uACR) and urinary protein/creatinine (uPCR) ratios, expressed as mg/g-Cr.
Because the Kidney Disease Improving Global Outcome (KDIGO) criteria combine elements from prior AKI definitions (Acute kidney injury network -AKIN and RIFLE criteria), it was used to classify our patients [21] . AKI stage 1 was defined as an increase in serum creatinine (SCr) ≥0.3 mg/dl and 1.5-1.9-fold increase in relation to the basal SCr. AKI stage 2 was defined as a 2.0-2.9-fold increase and AKI stage 3 as a 3-fold increase in relation to the basal SCr. Basal SCr was the lowest SCr level measured during hospital stay.
Enzyme-linked immunosorbent assay (ELISA)
Biomarker levels were measured using enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, MN, USA). In total, urinary and serum NGAL (DY1757-Duoset, R&D Systems), urinary KIM-1 (DY1750B-Duoset, R&D Systems) and urinary MCP-1 (DY279-Duoset, R&D Systems) levels were all evaluated in duplicate. Moreover, IFN-y (DY285-Duoset, R&D Systems) and C-reactive protein (CRP: DY1707-Duoset, R&D Systems) levels were quantified in serum samples. To control for urine concentration differences, urinary biomarkers were expressed according to the urinary creatinine content and expressed as 'mg-Cr'.
All these assays were sandwich ELISA. Briefly, 96 well plates (UltraCruz â ELISA Plate) were coated for the specific capture of anti-human biomarker antibodies, followed by human biomarker binding after adding diluted human samples; binding of biotinylated detection antibodies with epitopes of human biomarker that were fixed by capture antibodies; conjugation of streptavidin-horseradish peroxidase with biotin of the previously immobilised biotinylated antibodies; and quantification of immobilised antibody-biotin-streptavidin-enzyme conjugates by monitoring horseradish peroxidase activity in the presence of the substrate 3,3 0 ,5,5 0 -tetra-methylbenzidine (TMB ELISA substrate (high sensitivity), Abcam, Cat. No ab171523, Cambridge, MA). Finally, enzyme activity was measured by spectrophotometry at 450 nm, with wavelength correction of 570 nm. The increase in absorbance was directly proportional to the concentration of the analysed biomarker in the sample.
Statistical analyses
Categorical data were expressed as frequency counts and percentages and compared using the chi-square test. All quantitative variables were tested for normal distribution using the Shapiro-Wilk test. Normally or near-normally distributed variables are reported as mean AE standard deviation, whereas median with the interquartile range (IQR) was used for non-normal data. The Student's t test, one-way analysis of variance (ANOVA) with Tukey posttest, or the Kruskal-Wallis with Dunn's post-test was applied to compare means/medians of continuous variables according to the distribution of data between the groups. Correlations between clinical and novel kidney biomarkers were evaluated using Pearson's correlation or Spearman's rank correlation, as appropriate. Moreover, partial (adjusted) correlation was evaluated after controlling for IFN-y and CRP levels. Logistic regression models were used to evaluate the association between kidney biomarkers and AKI development in VL patients after adjusting for age, gender, variables involved in VL complications (levels of globulins, albumin, aspartate aminotransferase, haemoglobin, white blood cells and platelets), IFN-y and CRP levels. The linearity between continuous variables and the outcome was tested using the Box-Tidwell test [22] . Briefly, interactions between the continuous predictors and their logs were included in the model. If such interactions were significant, then the linearity assumption had been violated. Improvement in the maximum log-likelihood stepwise method after the kidney biomarker inclusion was used to evaluate the regression model. The ability of renal biomarkers levels in predicting AKI in VL patients at admission was assessed using the area under the receiver operator characteristic curve (AUC-ROC) as well as the cut-off, sensitivity and specificity values. The statistical analysis was performed using the IBM SPSS Statistics for Windows, version 20.0 (IBM, USA). Vertical scatter plots were created using GraphPad Prism 5 for Windows (version 5.01).
Results
Demographic, clinical and laboratory parameters in VL patients
Serum and urine samples were collected from 82 VL patients, but after applying the exclusion criteria, 50 patients were included. Among the excluded patients (n = 32), 10 (31.3%) had hypertension or diabetes, six (18.7%) had serum creatinine level >2 mg/dl at admission and 16 patients (50%) had a hospital stay <48 h ( Figure 1 ). They were mostly males (86%) and their mean age was 45 AE 19 years. VL patients had important disorders caused by the Leishmania infestation, such as haematologic disorders (decrease in levels of haemoglobin, haematocrit, platelets and white blood cells counts), hypoalbuminemia, hypergammaglobulinemia and hepatic disorders, with higher levels of enzymes and total bilirubin (Table 1) .
VL patients were divided into AKI and No AKI groups, according to the AKI development during hospital stay. The AKI development was observed in 23 patients (46%), and three of them had AKI stage 2 (6%), whereas 20 cases had AKI stage 1 (40%). Among the VL patients followed during hospital stay, one died (2%); this patient developed AKI stage 2. The AKI group showed significant longer hospital stay. Moreover, the use of amphotericin B at some time during hospital stay was more frequent in the AKI group, albeit not statistically significant. At admission, the AKI group had a higher mean level of serum creatinine, urea and decreased eGFR than the no AKI group and healthy controls. uPCR and uACR were elevated in both VL patient groups ( Table 1) .
Evaluation of kidney injury biomarkers in VL patients
Regarding the kidney injury biomarkers, serum and urinary NGAL (sNGAL and uNGAL), urinary KIM-1 (uKIM-1) and urinary MCP-1 (uMCP-1) were elevated in the AKI group (Figure 2) . The mean level of sNGAL was increased in the AKI group vs. the No AKI group (200.3 AE 59.1 vs. 136.1 AE 56.2 ng/ml, P < 0.01) and even in the No AKI group in comparison with the healthy controls (136.1 AE 56.2 vs. 82.8 AE 27 ng/ml, P < 0.01). The mean uNGAL (15.8 AE 8.4 ng/mg-Cr) and uKIM-1 (2.21 AE 2.0 ng/mg-Cr) levels and the median and interquartile range of uMCP-1 level (427, 72-659, pg/mg-Cr) were significantly higher (P < 0.05) only in the AKI group, when compared with the healthy controls. Regarding the inflammatory biomarkers, the mean level of C-reactive protein (CRP) was higher in VL patients when compared with the healthy controls (P < 0.001). On the other hand, the systemic levels of IFN-y were lower in VL patients than in the healthy controls (P < 0.001) ( Table 1) .
Correlations of kidney injury biomarkers and clinical renal parameters in VL patients
The correlations analysis was performed to evaluate whether the levels of novel kidney biomarkers were associated with clinical renal parameters in VL patients before the start of specific treatment against Leishmania. Moreover, to assess a possible interference of immunological factors in these correlations, adjusted correlations using systemic levels of IFN-y and CRP were applied to previous significant (P < 0.05) correlations (Table 2) .
Urinary KIM-1 (uKIM-1), a proximal tubule injury biomarker, showed moderate correlations with serum creatinine (r = 0.389, P = 0.017), serum urea (r = 0.397, P < 0.05), uPCR (r = 0.419, P < 0.05), uACR (r = 0.442, P < 0.01) levels, whereas an inverse correlation was observed with serum sodium (r = À0.490, P < 0.05). After adjusting for IFN-y and CRP levels, uKIM-1 remained correlated only with uPCR (r = 0.577, P < 0.05). Urinary MCP-1 (uMCP-1) and urinary NGAL (uNGAL) were correlated with uACR; however, only uMCP-1 remained associated after adjusting correlation (r = 0.571, P < 0.05).
Concerning sNGAL levels, there were positive correlations between serum creatinine (r = 0.487, P < 0.001), urea (r = 0.583, P < 0.001), and uACR (r = 0.350, P < 0.05) levels and a negative correlation with eGFR (r = À0.447, P < 0.01). In the adjusted correlations, sNGAL remained correlated with creatinine, urea, decreased eGFR and uACR. Hence, sNGAL was associated with most of the important clinical renal parameters, even with the influence of IFN-y mediator and systemic inflammation represented by CRP in VL patients.
Association of kidney injury biomarkers with AKI development during hospital stay
In a logistic regression model, only sNGAL levels at admission were significantly associated with AKI Figure 1 Flow chart of visceral leishmaniasis patients that were evaluated in this study, including those that were divided into Acute Kidney Injury (AKI) groups. development in the univariate analysis (OR = 2.785 and 95% CI = 1.429-5.428 per increase of 50 ng/ml in sNGAL). In different multivariate models using variables associated with VL severity and inflammation (age, gender, haemoglobin, white blood cells, platelets, serum globulins and albumin, aspartate aminotransferase, IFN-y and CRP levels), sNGAL maintained an important association with AKI development in VL patients (model 1: OR = 3.107 and 95% CI = 1.407-6.858; model 2: OR = 3.507 and 95% CI = 1.075-11.448 per each increase of 50 ng/ml in sNGAL) ( Table 3) .
A receiver operating characteristic (ROC) curve was constructed to display the true positive rate (sensitivity) and false positive rate (1 -specificity) of different kidney injury biomarker cut-offs for predicting AKI in VL patients. Also, the performance of each biomarker was assessed by the area under the receiver operator characteristic curve (AUC-ROC). Only sNGAL and uNGAL could detect AKI with statistical significance. uNGAL had an AUC-ROC = 0.68 (95% CI = 0.52-0.83), with a cut-off = 10.6 ng/mg-Cr it had a sensitivity = 69.6% and specificity = 63% (P = 0.029). However, sNGAL had the Data are presented as the mean AE standard deviation or as an absolute number with percentage in parentheses. GFR, glomerular filtration rate using CKD-EPI formula; uPCR, urinary protein/creatinine ratio; uACR, urinary albumin-creatinine ratio; sNGAL and uNGAL, serum and urinary neutrophil gelatinase-associated lipocalin, respectively; uKIM-1, urinary kidney injury molecule-1; uMCP-1, urinary monocyte chemotactic protein-1; CRP, C-reactive protein; IFN-y, interferon-gamma. *P < 0.05 compared with healthy control. **P < 0.05 compared with 'No AKI'. ***P < 0.05 compared with healthy control and 'No AKI' group.
better performance among biomarkers with the highest AUC-ROC - Figure 3 . sNGAL levels had an AUC-ROC = 0.81 (95% CI = 0.69-0.93) and with a cut-off = 154 ng/ml it had a sensitivity = 82.6% and specificity = 74.1% (P < 0.001).
Sensitivity analysis
Because only sNGAL remained associated with AKI after multivariate adjustment, we performed a sensitivity analysis using its cut-off point (Table 3 ). sNGAL levels above of the cut-off (154 ng/ml) remained associated with AKI development in the univariate (OR = 13.571 and 95% CI = 3.416-53.926; P < 0.001) and multivariate models (Model 1: OR = 16.506 and 95% CI = 3.105-87.745; P = 0.001/model 2: OR = 28.825 and 95% CI = 2.094-396.734; P = 0.012).
Discussion VL-associated nephropathy is an important cause of patient morbimortality in VL and is often detected too late. To our knowledge, this is the first study to investigate the role of early AKI biomarkers, such as NGAL and KIM-1, in VL-associated nephropathy. We evaluated their early association with important well-established renal abnormalities in VL patients, before the start of the specific treatment, as well as in the presence of AKI development during hospital stay. Amphotericin B and pentavalent antimonial compounds are considered the most effective treatment against Leishmania and, in Brazil, the choice is based on the assistant physician's preference. National guidelines have not standardised any treatment preference [23] .
Although we excluded patients with creatinine >2 mg/dl, patients with reduced renal function at baseline were less frequently treated with amphotericin B. In VL animal and human studies, VL-associated nephropathy has been attributed to mechanisms that lead to interstitial nephritis and glomerular changes [24] . In the present study, the VL patients showed signs of both interstitial and glomerular injury due to the leishmaniasis infection itself, evidenced before the start of the treatment. We observed higher proteinuria and albuminuria levels in VL patients. In VL, glomerular damage has been characterised as a mesangial proliferative lesion or deposition of immune complexes, leading to rapidly progressive glomerulonephritis [8, 25] . Elevated proteinuria can be a result of hypergammaglobulinemia in VL patients with low molecular weight protein fractions such as alpha 1, alpha 2, beta microglobulins and especially gamma globulins, which were freely filtrated in the glomeruli. Elevated proteinuria may accelerate kidney disease progression through chemokine induction and complement activation, which lead to inflammatory cell infiltration in the interstitium [26] .
Overall, our best results were found with serum NGAL level evaluation. NGAL levels at admission were significantly higher in VL patients that developed AKI and were independently associated with AKI development in the univariate and multivariate analyses, even after adjustment for clinical markers of VL severity and systemic inflammation. In the present study, we used the KDIGObased AKI classification. This classification differs from the RIFLE and AKIN classifications, especially regarding the time criterion. KDIGO covers both the AKIN and RIFLE criteria, taking into account changes in creatinine within 48 h (0.3 md/dl increment in serum creatinine) AKI was defined according to the KDIGO criteria and treated as a dependent variable in the logistic regression analysis. sNGAL and uNGAL, serum and urinary neutrophil gelatinase-associated lipocalin, respectively; uKIM-1, urinary kidney injury molecule-1; uMCP-1, urinary monocyte chemotactic protein-1. Model 1: adjusted for age, gender, haemoglobin, white blood cells, platelets, interferon-gamma (IFN-y) and C-reactive protein (CRP). Model 2: adjusted for age, gender, globulins, albumin, aspartate aminotransferase (AST), IFN-y and CRP. CI, confidence interval; OR, odds ratio. *Log-likelihood reduction after sNGAL addition v 2 14.05, df = 1, P < 0.01. **Log-likelihood reduction after sNGAL addition v 2 13.8, df = 1, P < 0.01. and for a period of 7 days. sNGAL levels showed good sensitivity and specificity to predict AKI and it is a potential candidate to be included in the clinical care of such patients. Although amphotericin B is emerging as the first-line treatment against VL in some countries, pentavalent antimonial compounds continue to be successfully used. Using NGAL levels as biomarkers to direct the treatment of patients with VL can be an important approach to prevent additional nephrotoxic exposure in high-risk patients.
NGAL is released by activated neutrophils, an important component of antimicrobial innate immunity in the early stages of infection [27] . The higher levels of NGAL in the blood acts as a chemoattractant for neutrophils, promoting neutrophil adhesion, extravasation and phagocytosis and also activates CD4+ T regulatory cells [27] . Studies with Leishmania major (cutaneous leishmaniasis) and L. infantum (visceral leishmaniasis) reported that several aspects in the early innate immune reactions were related to neutrophil activation [2] . During the early stages of infection, the metacyclic promastigotes (infectious flagellated form of Leishmania) are phagocytosed by neutrophils that seem to help them to evade innate antimicrobial defence by macrophages [2] . As a result, the innate immunity fails to control infection and systemic disease with exacerbated and inefficient neutrophil activation. On the other hand, antigen-presenting cells (APCs) may capture dead parasites and presents to CD8+ and CD4+ cells, which have a huge importance for the control of Leishmania infections through IFN-y production [2] , as illustrated in Figure 4 . In addition, IFN-y seems to inhibit neutrophil recruitment and activate infected macrophages to kill parasites [2, 28] .
Thus we suggest that higher levels of systemic NGAL observed in our present VL patients may be associated with exacerbated and inefficient neutrophil activation, which contributes to the infection progression. On the other hand, intrinsic kidney injury resulting from VL Figure 3 Measurement of serum and urinary NGAL levels (sNGAL and uNGAL, respectively) at hospital admission for acute kidney injury diagnosis in visceral leishmaniasis patients. AUC-ROC: area under the receiver operator characteristic curve. Significant value: P < 0.05. infection and inflammation [8] may contribute to increased NGAL expression in nephron segments, leading to a further increase in both urinary and systemic NGAL [29] . Furthermore, any GFR impairment due to kidney injury contributes to a decrease in renal clearance of NGAL and, consequently, to an increase in NGAL circulation levels (Figure 4) .
In the present study, these systemic levels of NGAL were associated with AKI and showed a better performance than other biomarkers in predicting AKI development, including in comparison to urinary NGAL. Moreover, the levels above the best sNGAL cut-off in our ROC curve analysis showed an increased the risk for AKI development. This association may be affected by systemic immune responses. However, even after adjustment for important inflammatory variables (IFN-y and PCR) sNGAL remained associated with AKI development and clinical renal markers, suggesting an independent Glomerulonephritis and interstitial nephritis may be caused by glomerular ultrafiltration of excessive amounts of plasma proteins (protein overload), the leishmaniasis infection itself, immune complex deposition and renal inflammation. In this context, proteinuria and albuminuria increase and, furthermore, intrinsic MCP-1 (mostly in glomeruli) and KIM-1 (proximal tubular injury) are produced and excreted by renal cells. The innate immunity against Leishmania is associated with neutrophil recruitment and activation that produce and increase systemic NGAL, mostly in exacerbated neutrophil activation during inefficient leishmanicidal activity. During acute kidney injury, GFR impairment contributes to decrease renal clearance of NGAL and, consequently, to increase NGAL circulation. Also, NGAL expression is induced in tubule renal cells, leading to a further increase in both urinary and systemic NGAL. The host's immune response is crucial for the control of Leishmania infections through IFN-y production, which seems to inhibit neutrophil activation and recruitment. Abbreviations: APCs, antigen-presenting cells; IFN-y, interferon-gamma; GFR, glomerular filtration rate; uPCR, urinary protein/creatinine ratio; uACR, urinary albumin-creatinine ratio; sNGAL and uNGAL, serum and urinary neutrophil gelatinase-associated lipocalin, respectively; uKIM-1, urinary kidney injury molecule-1; uMCP-1, urinary monocyte chemotactic protein-1. association between sNGAL and AKI. NGAL has been extensively studied as a new biomarker for early AKI detection [13] . However, the evaluation of NGAL as a kidney injury predictor during tropical infectious diseases has been poorly investigated. Rocha et al. evaluated the diagnostic performance of urinary NGAL in 22 leishmaniasis patients (five patients had visceral and 17 were cutaneous leishmaniasis), focusing on amphotericin Binduced AKI. Urinary NGAL was measured during amphotericin B use and was elevated in the AKI group with AUC-ROC = 0.680 on day 5, the best performance among the 14 days of treatment [30] . In a previous study by our group with leptospirosis patients, serum NGAL levels were not associated with AKI, but were higher than in healthy controls [31] . To the best of our knowledge, there have been no studies evaluating the role of early AKI biomarkers in VL-associated nephropathy. We speculate that VL-associated nephropathy is more often associated with inflammatory mechanisms that seem not to be related with a very acute renal disease profile, as in other clinical settings. However, VL-associated nephropathy is an important risk factor for AKI development and must be investigated with more sensitive kidney biomarkers, such as NGAL.
MCP-1 plays a pivotal role in the pathogenesis of renal injury. MCP-1 is produced by intrinsic renal cells, such as podocytes, mesangial and endothelial cells, when stimulated by inflammatory inducers such as immune complexes [32] . Moreover, MCP-1 induced a significant reduction in nephrin expression in human podocytes, an important protein of the glomerular filtration barrier, and it is associated with albuminuria [33] . In this study, we observed higher levels of urinary MCP-1 (uMCP-1) that were correlated with an increase in albuminuria, even after testing inflammatory interference. Our previous studies with other infectious disease, including VL, hepatosplenic schistosomiasis and leprosy (mostly as the lepromatous form) showed patients also had these clinical complications, including urinary oxidative stress, suggesting an increased risk of kidney disease development in these patients [19, 34, 35] . Despite the important involvement of uMCP-1 in renal interstitium inflammation and glomerulonephritis in VL, the present study showed it was not related with AKI development in the univariate analysis and that it had a poor diagnostic performance in the ROC curve analysis.
We demonstrated for the first time elevated levels of urinary KIM-1 (uKIM-1) in VL patients before the use of medications against Leishmania, and it was correlated mostly with elevated proteinuria. KIM-1 was significantly expressed early in proximal tubular cells during kidney injury, but not detected in healthy kidneys [36, 37] .
Hence, we suggest that VL patients had an important injury in renal proximal tubules. Proximal tubulopathy was also suggested in a previous study through retinolbinding protein levels in VL patients [25] . A possible mechanism is acute tubulointerstitial nephritis observed in VL-associated nephropathy [38, 39] , which may be caused by elevated proteinuria, the Leishmania infection itself and inflammatory cell infiltration within the interstitium [40] . Evidence has shown that apical exposure to protein overload in proximal tubular cells induces a proinflammatory phenotype, leading to injury [41] . Thus, the glomerular ultrafiltration of excessive amounts of plasma proteins found in VL patients may induce tubulointerstitial damage, which can stimulate local KIM-1 expression and increase uKIM-1 excretion [41] . In fact, in this present study, uKIM-1 levels remained correlated only with proteinuria after adding the immune components' influence to the partial correlation. However, in the present study, uKIM-1 was not able to predict AKI in VL patients, despite being a promising biomarker for early detection of AKI in various population settings [36] .
The present study has important limitations. It was carried out with a small sample of VL patients. Such a relatively small number of individuals can imply in instability and/or overfitting of the logistic regression model, in addition to the difficulty in applying it to other geographical areas. Therefore, our data are important, but must be interpreted with caution. Although studies with large numbers of VL patients are difficult to perform, future evaluations of sNGAL in similar patients (other infectious diseases, patients receiving nephrotoxic drugs) can reinforce our findings. Also, although we evaluated several laboratory parameters, clinical complications of VL that are associated with mortality [3, 8] , such as bacterial infections, dyspnoea and diarrhoea were not included in the present study. Moreover, the study was performed in a single centre, although most VL patients from our endemic areas are referred to this important hospital. Hence, our AKI rates may not be extrapolated to the entire VL population.
In conclusion, we suggest that there is important proximal tubular injury related to protein overload in renal tissue and a glomerular filtration barrier dysfunction associated with glomerular inflammation, but the exact mechanisms remain to be fully elucidated. For the first time, serum NGAL was independently associated with VL-associated nephropathy and it was the most reliable biomarker to predict the risk for AKI development in VL patients. Finally, aiming at reducing patient morbimortality, we believe that serum NGAL can be used in clinical practice to improve clinical management strategies and prevent the immediate exposure to additional nephrotoxic drugs in hospitalised VL patients with a high risk of AKI development.
